✉news TechnologyAI first seen 2 d ago, last 2 d ago, peak #12
AstraZeneca signs $1.5 billion AI drug discovery deal with insitro
Original: AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs
AstraZeneca has agreed a deal worth up to $1.5 billion with AI drug discovery firm insitro to use machine learning to identify new drug targets for liver and heart diseases. The partnership pairs AstraZeneca's clinical expertise with insitro's data-driven discovery platform, reflecting the pharmaceutical industry's growing reliance on artificial intelligence to speed up early-stage research.
Why now: It is a major new example of big pharma investing in AI for drug discovery, a fast-moving area of interest.
Evidence
- AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs · Fierce Biotech
API: https://socialmediatrends-api.osmike.com/v1/trends/2369727